Foghorn Therapeutics (Foghorn Therapeutics) Gross Profit : $34.16 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Foghorn Therapeutics Gross Profit?

Foghorn Therapeutics's gross profit for the three months ended in Dec. 2023 was $5.77 Mil. Foghorn Therapeutics's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $34.16 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Foghorn Therapeutics's gross profit for the three months ended in Dec. 2023 was $5.77 Mil. Foghorn Therapeutics's Revenue for the three months ended in Dec. 2023 was $5.77 Mil. Therefore, Foghorn Therapeutics's Gross Margin % for the quarter that ended in Dec. 2023 was N/A%.

Foghorn Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

Foghorn Therapeutics Gross Profit Historical Data

The historical data trend for Foghorn Therapeutics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Foghorn Therapeutics Gross Profit Chart

Foghorn Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Profit

Get a 7-Day Free Trial

0.43

1.32

19.23

34.16

Foghorn Therapeutics Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Profit	Get a 7-Day Free Trial															4.18	5.31	5.60	17.48	5.77

Competitive Comparison of Foghorn Therapeutics's Gross Profit

For the Biotechnology subindustry, Foghorn Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Foghorn Therapeutics's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Foghorn Therapeutics's Gross Profit distribution charts can be found below:

* The bar in red indicates where Foghorn Therapeutics's Gross Profit falls into.

Foghorn Therapeutics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Foghorn Therapeutics's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )	=	Revenue	-	Cost of Goods Sold
	=	34.155	-	0
	=	34.16

Foghorn Therapeutics's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )	=	Revenue	-	Cost of Goods Sold
	=	5.769	-	0
	=	5.77

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $34.16 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Foghorn Therapeutics's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	5.77	/	5.769
	=	N/A %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Foghorn Therapeutics (NAS:FHTX) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Foghorn Therapeutics had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

Foghorn Therapeutics Gross Profit Related Terms

Thank you for viewing the detailed overview of Foghorn Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.

Foghorn Therapeutics (Foghorn Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Foghorn Therapeutics Inc (NAS:FHTX) » Definitions » Gross Profit

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Technology Square, Suite 700, Cambridge, MA, USA, 02139

Website

https://www.foghorntx.com

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Executives

Alfonso Quintas Cardama	officer: Chief Medical Officer	C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Samuel Agresta	officer: Chief Medical Officer	784 MEMORIAL DR., CAMBRIDGE MA 02139
Lynch Thomas J. Jr.	director	800 HOWARD AVENUE, YALE PHYSICIANS BUILDING, 2ND FLOOR, NEW HAVEN CT 06519
B Lynne Parshall	director	2855 GAZELLE COURT, CARLSBAD CA 92010
Carlos Costa	officer: Chief People Officer	C/O FOGHORN THERAPEUTICS INC., 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Fanny Cavalie	officer: Chief Strategy/Bus Ops Officer	C/O FOGHORN THERAPEUTICS INC., 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Ian F Smith	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Michael Lacascia	officer: Chief Legal Officer	500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Carl Decicco	officer: Chief Scientific Officer	100 BINNEY STREET, SUITE 610, CAMBRIDGE MA 02142
Flagship Ventures Opportunities Fund I General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Abu Dhabi Investment Authority	10 percent owner	211 CORNICHE STREET, PO BOX 3600, ABU DHABI C0 0000
Michael Mendelsohn	director	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Adam Koppel	director	C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Steven F. Bellon	officer: See Remarks	500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Jose Baselga	director	780 MEMORIAL DRIVE, CAMBRIDGE MA 02139